Pre Market Trading Indications

Gapping up in reaction to strong earnings/guidance: BBY +6.7%, BLUD +5.9%, EXFO +4.9%, KMX +3.1%...

Solar stocks showing strength with select co specific news out: CSUN +4.1%, TSL +3.8% (announced that the co has signed a long-term polysilicon supply agreement with a subsidiary of GCL Silicon Technology Holdings), EMKR +3.2%, SOLF +2.8%, EMKR +1.9% (receives $4.6 mln follow-on order for concentrator solar cell receiver assemblies from Concentration Solar la Mancha), STP +1.6% (to supply 4MW of modules to 'leading' Italian PV system developer Enerray), ESLR +1.0%...

Select gold stocks showing strength with higher spot prices: GOLD +4.4%, IAG +4.3%, AU +1.7%, ABX +1.4%, GLD +1.3%, GFI +1.1%...

Other news: TKO +19.8% (awarded exclusive 2-yr contract for hospitality energy efficiency program), SVA +14.9% (receives China State Food and Drug Administration approval for pandemic influenza H5N1 vaccine), CPST +7.0% (receives HEV bus order for $5 mln from DesignLine International), NCC +5.6% (in talks with KeyCorp - WSJ), CC +3.6% (up in sympathy with BBY), KKD +3.2% (seeks amendments to credit facilities), AMAT +2.6% (Cramer makes positive comments on MadMoney), FIC +2.2% (announces reengineering plan; expects to reduce cost structure by $100 mln, yield annual pre-tax savings of $35 mln and a Q2 charge of $7 mln), NOK +2.1% (still checking), CVTX +2.1% (announces Ranexa significantly reduces cardiac chest pain symptoms and recurrent ischemia in merlin-timi 36 patients with angina), BCE +2.0% (BCE deal will proceed as planned, adviser says - Globe and Mail), AER +2.0% (announced its subsidiary AeroTurbine entered into a ten year component lease agreement signed between British Airways and AeroTurbine), SIRT +1.8% (receives orphan drug designation from FDA for Resveratrol in Mitochondrial Disorder, MELAS syndrome), STM +1.5% (announces its Board has authorized the co repurchase up to 30 mln common shares), NBR +1.5% (Cramer makes positive comments on MadMoney)...

Analyst upgrades: VRUS +6.1% (upgraded to Buy at UBS), VIP +3.0% (upgraded to Buy at tier 1 firm), HRS +1.3% (initiated with Buy at UBS).